| Literature DB >> 27011859 |
Eyal Amar1, Zachary T Sharfman1, Ehud Rath1.
Abstract
Heterotopic ossification (HO) after hip arthroscopy is the abnormal formation of mature lamellar bone within extra skeletal soft tissues. HO may lead to pain, impaired range of motion and possibly revision surgery. There has been a substantial amount of recent research on the pathophysiology, prophylaxis and treatment of HO associated with open and arthroscopic hip surgery. This article reviews the literature on the aforementioned topics with a focus on their application in hip arthroscopy.Entities:
Year: 2015 PMID: 27011859 PMCID: PMC4732379 DOI: 10.1093/jhps/hnv052
Source DB: PubMed Journal: J Hip Preserv Surg ISSN: 2054-8397
Fig. 1.Heterotopic ossification is initiated local tissue damage leading to increased BMP-2 targeting of sensory nerves. Subsequently, a cascade of molecular mechanisms including the binding of SP and CGRP to mast cell and sympathetic signaling induces the remodeling of peripheral nerves. This remodeling initiates the production of chondro-osseous, glial, vascular and neural progenitor cells. These new cells respond to signals from transient brown adipocytes that regulate local oxygen content, vascularization and innervation to produce HO. (Reproduced with permission from reference [9].)
Fig. 2.Follow up radiograph of a 20-year-old patient after bilateral hip arthroscopy. The radiograph was taken 9 months status post left and 3 months status post right hip arthroscopy. HO on the left side was evident on radiographs 10 weeks after the index procedure. NSAID prophylaxis using etodolac 600 mg once daily for 2 weeks was administered only after the operation on the right hip.
Fig. 3.3D CT reconstruction of a 34-year-old triathlete showing grade 3 HO with acetabular origin and posterolateral location of the HO.
A literature review of relevant articles regarding the rates of HO after hip arthroscopy with and without prophylactic measures
| Author | Prophylaxis | HO (%) | Male/Female | Excision surgery |
|---|---|---|---|---|
| Larson | None | 6/96 (6.2%) | 54/42 | None of the patients required surgical excision. |
| Clohisy | None | 4/35(11.4%) | 28/7 | None of the patients required surgical excision |
| Randelli |
15 patients—etoricoxib 90 mg × 1/day for 3 weeks 248 patients—naproxen 500 mg × 2/day for 3 weeks 22 patients—other NSAIDs (aceclofenac, ketoprofen, indomethacine) for 3 weeks 15 patients—no prophylaxis (control) |
Study—0/285 (0%) Control—5/15 (33%) |
Control—9/6 Study—171/114 HO—4/1 | NA |
| Beddi |
Protocol 1—277 patients—naproxen 500 mg × 2/day for 30 days Protocol 2—339 patients—Indomethacine 75 mg daily for 4 days + Protocol 1 |
Protocol 1—23/277(8.3%) Protocol 2—6/339(1.8%) |
Protocol 1—154/123 Protocol 2—188/151 HO—21/8 |
7 patients 6 received protocol 1 Mean time to surgery—11.6 months Male/Female—6/1 |
| Rath | None | 22/50(44%) |
31/19 HO—15/7 | None of the patients required surgical excision |
| Beckman |
Control—92 patients 196 patients—naproxen 500 mg × 2/day for 3 weeks |
Control—23/92(25%) Study—11/196(5.6%) |
Control—41/51 Study—75/121 |
9 patients Control—4 patients Study—5 patients Mean time to surgery > 12 min |